Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.90 enrolled

Overview

The purpose of this study is to assess the safety and efficacy of IMM0306-02 in patients with refractory or relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

B-cell Non-Hodgkin's Lymphoma

Interventions

IMM0306DRUG

IMM0306 is an bi-specific antibody

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18-75 years old * Diagnosed with B-NHL * Relapsed after or be refractory to at least 2 line of standard therapy Exclusion Criteria: * Active central nervous system (CNS) metastases * Positive Direct Antiglobulin Test (DAT) * Active autoimmune disorder * Skin disorders that do not requires hormone replacement therapy

Locations (1)

The Christ Hospital

Cincinnati, Ohio, United States

Outcomes

Primary Outcomes

Maximum Tolerated Dose (MTD) of IMM0306 as measured by incidence of DLTs (Dose Limiting Toxicity)

DLT is defined as one of the following toxicities occurring during the DLT assessment for Cycle 1.

Time frame: End of Study (52 Weeks)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.